Current Assets
Cash, Cash Equivalents, and Marketable Securities
Amgen Cash, Cash Equivalents, and Marketable Securities increased by 16.3% to $8.71B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 1.5%, from $8.58B to $8.71B. Over 4 years (FY 2020 to FY 2024), Cash, Cash Equivalents, and Marketable Securities shows an upward trend with a 3.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityVolatile
First reportedQ3 2018
Last reportedQ4 2025
How to read this metric
Higher levels indicate strong liquidity and financial health, while lower levels may signal a need for external financing.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term invest...
Peer comparison
A standard liquidity metric reported by virtually all public companies on the balance sheet.
Metric ID:
cash_equivalents_marketable_securities_totalHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.16B | $12.28B | $7.30B | $5.85B | $6.41B | $10.92B | $4.34B | $31.07B | $33.62B | $34.21B | $10.40B | $9.24B | $8.81B | $8.58B | $11.49B | $8.30B | $7.49B | $8.71B |
| QoQ Change | — | +71.5% | -40.5% | -19.9% | +9.6% | +70.3% | -60.3% | +616.6% | +8.2% | +1.8% | -69.6% | -11.2% | -4.6% | -2.7% | +33.9% | -27.7% | -9.8% | +16.3% |
| YoY Change | — | — | — | — | -10.4% | -11.0% | -40.6% | +430.8% | +424.2% | +213.2% | +140.0% | -70.3% | -73.8% | -74.9% | +10.4% | -10.1% | -15.0% | +1.5% |
Range$4.34B – $34.21B
CAGR+4.7%
Avg YoY Growth+65.3%
Median YoY Growth-10.3%
Cash, Cash Equivalents, and Marketable Securities at Other Companies
Frequently Asked Questions
- What is Amgen's cash, cash equivalents, and marketable securities?
- Amgen (AMGN) reported cash, cash equivalents, and marketable securities of $8.71B in Q3 2025.
- How has Amgen's cash, cash equivalents, and marketable securities changed year-over-year?
- Amgen's cash, cash equivalents, and marketable securities increased by 1.5% year-over-year, from $8.58B to $8.71B.
- What is the long-term trend for Amgen's cash, cash equivalents, and marketable securities?
- Over 4 years (2020 to 2024), Amgen's cash, cash equivalents, and marketable securities has grown at a 3.9% compound annual growth rate (CAGR), from $9.85B to $11.49B.
- What does cash, cash equivalents, and marketable securities mean?
- The total value of the company's cash and highly liquid short-term investments.